RxDoctor Payments Data

Tyisha Davis

Psychiatric/Mental Health · Friendswood, TXNPI 1275121055

Payments from drug & device makers

$12,008in general payments, 2019–2025

Across 582 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Axsome Therapeutics, Inc.$892
  • Corium, LLC$766
  • plus $5K from 19 others

What the payments were for

  • Food & beverage$11,91199%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,008 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$3,497
Medicare patients
11
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$85,246
LybalviOlanzapine/Samidorphan Malate18$30,537
AuvelityDextromethorphan Hbr/Bupropion11$12,289
BelsomraSuvorexant18$8,193
Aripiprazole61$6,704
Lurasidone Hcl11$3,244
Duloxetine Hcl30$1,505
Hydroxyzine Hcl36$1,036
Buspirone Hcl45$835
Quetiapine Fumarate35$668
Divalproex Sodium27$625
Mirtazapine41$590
Venlafaxine Hcl ErVenlafaxine Hcl26$579
Bupropion XlBupropion Hcl28$514
Olanzapine37$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,529$85,24623 claims
Alkermes, Inc.Lybalvi$649$30,53718 claims
Axsome Therapeutics, Inc.Auvelity$892$12,28911 claims
Almatica Pharma LLCSertraline Hcl$17$25067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Friendswood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →